hydroxychloroquine has been researched along with Thrombocytopenia in 12 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 56 year old woman with rheumatoid arthritis developed relapsing thrombocytopenia during successive treatments with aurothioglucose, sulphasalazine, and hydroxychloroquine." | 7.68 | Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. ( Allebes, WA; Boerbooms, AM; van de Putte, LB; van Riel, PL; Wijnands, MJ, 1990) |
| "A 56 year old woman with rheumatoid arthritis developed relapsing thrombocytopenia during successive treatments with aurothioglucose, sulphasalazine, and hydroxychloroquine." | 3.68 | Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. ( Allebes, WA; Boerbooms, AM; van de Putte, LB; van Riel, PL; Wijnands, MJ, 1990) |
| "Hydroxychloroquine (HCQ) use was found as a protective factor for CVD." | 1.43 | Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. ( Alpay-Kanıtez, N; Aral, O; Artim-Esen, B; Demir, S; Erer, B; Gül, A; İnanç, M; Kamalı, S; Öcal, L; Omma, A; Pehlivan, Ö; Şahinkaya, Y, 2016) |
| "In 22 SLE patients with chronic renal insufficiency (median serum creatinine clearance 52 ml/minute [range 23-58 ml/minute]) who received 400 mg/day HCQ, the median blood HCQ concentration was significantly higher than that in the 509 patients from the PLUS study (1,338 ng/ml [range 504-2,229 ng/ml] versus 917 ng/ml [range 208-3316 ng/ml]) (P < 0." | 1.42 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. ( Ackermann, F; Amoura, Z; Asli, B; Aumaître, O; Blanchet, B; Cacoub, P; Cohen-Bittan, J; Costedoat-Chalumeau, N; Desmurs-Clavel, H; Fain, O; Francès, C; Galicier, L; Hulot, JS; Jallouli, M; Kahn, JE; Le Guern, V; Le Thi Huong, D; Leroux, G; Limal, N; Lioté, F; Mariette, X; Papo, T; Perard, L; Piette, JC; Pourrat, J; Sacré, K; Sailler, L; Sellam, J; Smail, A; Stirnemann, J; Zahr, N, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Y | 2 |
| Huang, C | 1 |
| You, H | 1 |
| Zhao, J | 1 |
| Wang, Q | 1 |
| Tian, X | 1 |
| Li, M | 1 |
| Zeng, X | 1 |
| Sun, F | 1 |
| Tang, Q | 1 |
| Cheng, W | 1 |
| Xie, X | 1 |
| Li, F | 1 |
| Chen, J | 1 |
| Kuraitis, D | 1 |
| Murina, A | 1 |
| Sheha, D | 1 |
| El-Shayeb, M | 1 |
| Eid, Y | 1 |
| Amin, M | 1 |
| Saeed, A | 1 |
| Abdou, D | 1 |
| Aly, T | 1 |
| Samy, S | 1 |
| Elziaty, R | 1 |
| Aboelyazed, S | 1 |
| Osman, A | 1 |
| Sheha, A | 1 |
| Mok, CC | 1 |
| Ho, LY | 1 |
| Tse, SM | 1 |
| Chan, KL | 1 |
| Shin, S | 1 |
| Park, SH | 1 |
| Park, J | 1 |
| Levy, R | 1 |
| Mahévas, M | 1 |
| Galicier, L | 2 |
| Boutboul, D | 1 |
| Moroch, J | 1 |
| Loustau, V | 1 |
| Guillaud, C | 1 |
| Languille, L | 1 |
| Fain, O | 2 |
| Bierling, P | 1 |
| Khellaf, M | 1 |
| Michel, M | 1 |
| Oksenhendler, E | 1 |
| Godeau, B | 1 |
| Jallouli, M | 1 |
| Zahr, N | 1 |
| Aumaître, O | 1 |
| Francès, C | 1 |
| Le Guern, V | 1 |
| Lioté, F | 1 |
| Smail, A | 1 |
| Limal, N | 1 |
| Perard, L | 1 |
| Desmurs-Clavel, H | 1 |
| Le Thi Huong, D | 1 |
| Asli, B | 1 |
| Kahn, JE | 1 |
| Pourrat, J | 1 |
| Sailler, L | 1 |
| Ackermann, F | 1 |
| Papo, T | 1 |
| Sacré, K | 1 |
| Stirnemann, J | 1 |
| Cacoub, P | 1 |
| Leroux, G | 1 |
| Cohen-Bittan, J | 1 |
| Sellam, J | 1 |
| Mariette, X | 1 |
| Blanchet, B | 1 |
| Hulot, JS | 1 |
| Amoura, Z | 1 |
| Piette, JC | 1 |
| Costedoat-Chalumeau, N | 1 |
| Demir, S | 1 |
| Artim-Esen, B | 1 |
| Şahinkaya, Y | 1 |
| Pehlivan, Ö | 1 |
| Alpay-Kanıtez, N | 1 |
| Omma, A | 1 |
| Erer, B | 1 |
| Kamalı, S | 1 |
| Gül, A | 1 |
| Aral, O | 1 |
| Öcal, L | 1 |
| İnanç, M | 1 |
| Caminal Montero, L | 1 |
| González Marroquín, A | 1 |
| Ferro Mosquera, J | 1 |
| Susano, R | 1 |
| Wijnands, MJ | 1 |
| Allebes, WA | 1 |
| Boerbooms, AM | 1 |
| van de Putte, LB | 1 |
| van Riel, PL | 1 |
| Muirden, KD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
2 reviews available for hydroxychloroquine and Thrombocytopenia
| Article | Year |
|---|---|
Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
Topics: Adolescent; Adult; Agammaglobulinemia; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Female | 2014 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
1 trial available for hydroxychloroquine and Thrombocytopenia
| Article | Year |
|---|---|
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
10 other studies available for hydroxychloroquine and Thrombocytopenia
| Article | Year |
|---|---|
Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study.
Topics: Adult; Anticoagulants; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ly | 2022 |
Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sjögren syndrome.
Topics: Hemorrhage; Humans; Hydroxychloroquine; Purpura, Thrombocytopenic, Idiopathic; Retrospective Studies | 2023 |
Facts, not Fear: Safety of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Agranulocytosis; Anemia, Aplastic; Antirheumatic Agents; | 2020 |
Unfolding of sickle cell trait by coronavirus disease 2019 (COVID-19) infection.
Topics: Adrenal Cortex Hormones; Anticoagulants; Azithromycin; Combined Modality Therapy; COVID-19; COVID-19 | 2020 |
Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Asian People; China; Databases, Factual; Female; Glucocorticoids; Human | 2017 |
Incidental Identification of Plasmodium vivax During Routine Complete Blood Count Analysis Using the UniCel DxH 800.
Topics: Antimalarials; Blood Cell Count; Humans; Hydroxychloroquine; Image Processing, Computer-Assisted; Ma | 2018 |
Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Body Mass Index; Creatinine; Female; Humans; H | 2015 |
Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Topics: Adult; Antibodies, Antiphospholipid; Antirheumatic Agents; Cardiovascular Diseases; Cross-Sectional | 2016 |
[Thrombopenia secondary to hydroxychloroquine].
Topics: Adult; Female; Humans; Hydroxychloroquine; Sjogren's Syndrome; Thrombocytopenia | 1994 |
Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Female; HLA-B8 Antigen; HLA-DR3 Antigen; Humans; Hydroxychlo | 1990 |